Perioperative antithrombotic management of patients who receive direct oral anticoagulants during gastroenterological surgery

Takahisa Fujikawa | Ryo Takahashi | Shigetoshi Naito

Department of Surgery, Kokura Memorial Hospital, Kitakyushu, Japan

Correspondence
Takahisa Fujikawa, Department of Surgery, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-Ku, Kitakyushu, Fukuoka 802-8555, Japan.
Email: fujikawa-t@kokurakinen.or.jp

Abstract
Aim: We investigated the effect of perioperative management of direct oral anticoagulants (DOACs) on bleeding and thromboembolic complications during gastroenterological (GE) surgery.

Methods: A total of 334 patients receiving anticoagulants and undergoing elective GE surgery between 2012 and 2018 were enrolled. The patients were divided into three groups: patients receiving warfarin (WF, n = 231), patients receiving DOACs with heparin bridging (DOAC-HB, n = 34), and patients receiving DOAC without heparin bridging (DOAC-NHB, n = 69). Outcome variables were compared between the groups and the risk factors of postoperative bleeding were assessed using logistic multivariate analysis.

Results: No significant differences were observed in background characteristics between the groups. There were similarities between the groups in surgical blood loss ($P = .772$) and rate of intraoperative transfusion ($P = .952$). Thromboembolic complications only occurred in two patients in the WF group (0.9%), and no thromboembolism occurred in the DOAC groups. The incidence of major postoperative bleeding was significantly higher in DOAC-HB group than in the other groups (14.7% vs 4.8% vs 1.4%, $P = .011$). Multivariate analysis showed DOAC with heparin bridging to be the most significant risk factor of major postoperative bleeding (odds ratio = 11.60, $P = .028$).

Conclusions: Elective GE surgery can be safely performed in patients receiving DOACs without heparin bridging. Perioperative heparin bridging during DOAC interruption is not recommended even for patients undergoing major GE surgery due to increased postoperative bleeding.

Keywords
anticoagulation therapy, bleeding complication, direct oral anticoagulant, gastroenterological surgery, thromboembolic complication
1 | INTRODUCTION

The number of patients who receive anticoagulation therapy (ACT) for the prevention of ischemic stroke or venous thromboembolism is increasing with the aging of the population. Since clinical trials showed non-inferiority or superiority of direct oral anticoagulant (DOAC) therapy over vitamin K antagonist (warfarin) therapy in terms of safety and efficacy for patients with atrial fibrillation, the number of patients who receive DOAC therapy has been increasing. Recent reports also indicate that approximately 10%–15% of patients treated with DOACs have to interrupt their anticoagulant treatment before an invasive procedure every year.

Direct oral anticoagulants, also known as non-vitamin K antagonist oral anticoagulants (NOACs), include direct thrombin inhibitors, such as dabigatran, and factor Xa inhibitors, such as rivaroxaban, apixaban, and edoxaban. The potential advantages of DOACs over warfarin include rapid onset and offset of action, reduced effect of dietary vitamin K intake or drug interaction on their activity, and predictable anticoagulant effects with no need for routine monitoring. Although updated guidelines on digestive endoscopic procedures indicate the optimal perioperative management for patients who receive DOAC treatment, perioperative management during gastroenterological (GE) surgery, which is considered to carry a high risk of bleeding, is yet to be established as it remains a challenge. In this study, we reviewed 334 consecutive patients who received ACT and underwent elective GE surgery, and we investigated the effect of perioperative management with DOACs on bleeding and thromboembolic complications.

2 | METHODS

2.1 | Patients

Our institutional review board approved this study (#19061903). We searched the prospectively collected surgery database of a single institution for relevant cases, and we included 334 consecutive patients who underwent GE surgery in this study and excluded patients who underwent emergency surgery (Figure 1). The cohort included 240 patients with malignant disease and 94 patients with benign disease, and, in terms of the mode of surgery, the cohort included 200 patients who underwent laparoscopic surgery and 134 patients who underwent open surgery. Based on the type of perioperative ACT, the patients were divided into three groups: patients who received warfarin therapy (WF group, n = 231), patients who received DOAC therapy with heparin bridging (DOAC-HB group, n = 34), and patients who received DOAC therapy without heparin bridging (DOAC-NHB group, n = 69). All procedures were performed by or under the guidance of one of the board-certified attending surgeons in our institution. The choice of perioperative ACT was based on patient condition and risk of thromboembolism. The management of patients with high thromboembolic risk included interruption of oral ACT, bridging anticoagulation with unfractionated heparin, and early postoperative reinstitution of oral ACT. In case of warfarin-received patients, warfarin was interrupted 5 days before the operation, heparin was started and continued until the day of surgery, warfarin and postoperative bridging with heparin were resumed on postoperative day (POD) 1–2 when hemostasis was secured, and discontinued bridging when the PT-INR was within therapeutic range. In case of DOAC-received patients with bridging heparin, DOAC was interrupted 1–3 days before the operation, heparin was started and continued until the day of surgery, DOACs and heparin bridging were resumed on POD 1–2, and heparin was discontinued on POD 4–5. If DOAC therapy was managed without bridging heparin, DOAC was stopped 0–1 days before the surgery and resumed 1–2 days after the surgery when hemostasis was secured.

If a patient received antiplatelet therapy such as aspirin or clopidogrel, the perioperative management was performed according to the previously described perioperative management protocol (the Kokura Protocol). Generally, antiplatelet agents were discontinued one week before surgery, but in patients with high thromboembolic risks, preoperative aspirin monotherapy was continued until the day before surgery. Postoperatively, early reinstitution of antiplatelets was performed unless there were signs of bleeding. For prevention of venous thromboembolism, mechanical prophylaxis (intermittent pneumatic compression and/or graduated compression stockings) and enforcement of early postoperative walking were generally performed, although routine use of medical prophylaxis with heparin was not adopted, except in the case of high venous thromboembolic risk patients with previous venous thrombosis or immobilization.

To assess the predicted thromboembolic risk of patients in each group, we used the revised CHADS2 scoring system, which is widely used for the prediction of ischemic stroke or transient ischemic attack (TIA) in patients with atrial fibrillation or atrial flutter. This scoring system is an assessment tool that evaluates congestive heart failure, hypertension, age, diabetes, and ischemic stroke, and it categorizes patients with a score of 2 or higher into the high-risk group. It has been reported that the revised CHADS2 scoring system
also predicts ischemic stroke and death in patients without a history of atrial fibrillation or atrial flutter. To assess the predicted bleeding risk of patients in each group, we used the HAS-BLED score, which is widely used for the predicting bleeding risk in anti-coagulated patients with atrial fibrillation.

The severity of patient symptoms and level of patient functioning in terms of ambulation were reported according to the Eastern Cooperative Oncology Group scale of performance status. Postoperative complications were assessed and categorized according to the Clavien-Dindo classification (CDC) and CDC class 2 or higher was considered significant. Postoperative thromboembolic complication was defined as per earlier reports. In brief, thromboembolism included cerebral infarction, myocardial infarction, mesenteric infarction, pulmonary thromboembolism, and acute arterial embolism. Postoperative bleeding complication was categorized by ISTH (International Society of Thrombosis and Haemostasis) definition, which included luminal bleeding (for example, gastrointestinal bleeding), abdominal bleeding, intracranial hemorrhage, and abdominal wall hematoma. Operative mortality was defined as death within 30 days after surgery.

The primary outcome included intraoperative blood loss and postoperative bleeding complications. The background characteristics, perioperative factors, and surgical outcomes of the included patients were compared between the groups, and the risk factors of postoperative bleeding complication were assessed using logistic multivariate analysis.

### 2.2 Statistical analysis

Continuous values were expressed as mean (standard deviation) or median (interquartile range), while categorical variables were presented as absolute numbers and percentages. For univariate comparisons, Fisher’s exact probability test was used to evaluate categorical variables, and continuous variables were analyzed using one-way analysis of variance and Kruskal-Wallis test for normally distributed data and non-normally distributed data, respectively. Multivariate logistic regression analysis was performed to determine the risk factors of thromboembolic complications. All P-values were two-sided, and P-values less than .05 were considered statistically significant. All statistical analyses were performed using EZR (Saitama Medical Centre, Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria, version 2.13.0).

### 3 RESULTS

#### 3.1 Patient and operative characteristics

A total of 334 patients were enrolled in this study. Figure 2 shows the types of anticoagulation agents administered to this cohort. Warfarin was the most commonly used agent and was administered to 231 of the 334 patients (69.2%), whereas DOAC was administered to 103 of the 334 patients (30.8%). Most patients in the WF group, a total of 226 out of 231 patients (97.8%), were perioperatively managed with heparin bridging. Of the 103 patients who received DOACs, 18, 29, 39, and 17 of them were administered dabigatran, rivaroxaban, apixaban, and edoxaban, respectively, and only 34 of the 103 patients (33.0%) received perioperative management with heparin bridging.

Table 1 shows the background characteristics of each group. The median ages in the WF, DOAC-HB, and DOAC-NHB groups were 75 years, 75 years, and 74 years, respectively (P = .927). There were also similarities between the groups in poor performance status of patients (grades 2–4) (P = .318), vascular diseases (P = .265), diabetes mellitus (P = .167), history of congestive heart failure (P = .116), abnormal liver function (P = .931), and history of cerebral infarction or TIA (P = .435) except for abnormal liver function (10.0% vs 0.0% vs 1.4%, P < .001). Concerning indication for ACT, non-valvular atrial fibrillation or flutter is the most prevalent in the whole cohort, and there was a difference in the rates of non-valvular (61.9% vs 79.4% vs 84.1%, P = .002) and valvular atrial fibrillation/flutter (10.8% vs 5.9% vs 0.0%, P = .030) between the groups. The rates of patients receiving antplatelet therapy and those treated by preoperative continuation of aspirin were identical between the groups. There was also no difference between the groups in the occurrence of patients with high bleeding risks categorized by HAS-BLED score (44.6% vs 38.2% vs 37.7%, P = .634).

The percentages of patients in the high-risk category according to the revised CHADS² scoring system in the WF, DOAC-HB, and DOAC-NHB groups were 57.6%, 61.8%, and 59.4%, respectively (P = .606).

Table 2 shows the factors associated with the operative procedures in the whole cohort. The cohort consisted of 94 patients with benign disease and 240 patients with malignant disease, and 191 esophagogastrointestinal resections and 113 hepatobiliary procedures in the whole cohort.
and pancreatic resections were performed. In terms of the mode of surgery, 200 patients underwent laparoscopic surgery, and 134 patients underwent open surgery. There were no statistically significant differences between the groups in the type of disease (P = .373) and type of surgery (P = .952), but laparoscopic surgery was less frequently performed in the WF group than in the DOAC-HB group and the DOAC-NHB group (54.5% vs 67.6% vs 73.9%, P = .009). Although there were similarities in surgical blood loss (P = .772) and rate of intraoperative red blood cell (RBC) transfusion (P = .919) between the groups, the duration of operation was shorter in the WF group than in the DOAC-HB group and the DOAC-NHB group (177 minutes vs 195 minutes vs 222 minutes, P = .035).

### 3.2 Postoperative bleeding and thromboembolic complications

Table 3 shows the factors associated with postoperative morbidity and mortality in the cohort. Postoperative complications occurred in 95% of the 334 patients (28.4%). The incidences of severe postoperative complications (CDC class 3 or higher) in the WF, DOAC-HB, and DOAC-NHB groups were 8.7%, 20.6%, and 5.8%, respectively (P = .071). Thromboembolic complications were observed in only two of the 231 patients (0.9%) in the WF group (cerebral infarction in one patient and pulmonary embolism in the other), but thromboembolism did not occur in any patient treated with a DOAC.
The incidence of major postoperative bleeding complication was significantly higher in the DOAC-HB group than in the WF group and the DOAC-NHB group (14.7% vs 4.8% vs 1.4%, \( P = .011 \), Figure 3). There was only a single case of postoperative bleeding (abdominal wall hematoma) in the DOAC-NHB group, which occurred on POD 49 after pancreaticoduodenectomy and persistent postoperative pancreatic fistula, in a patient receiving both apixaban and aspirin, and required repeated hemostasis. Postoperative bleeding occurred in five patients in the DOAC-HB group, which included three with gastrointestinal bleeding requiring endoscopic hemostasis (anastomotic bleeding in two and bleeding from gastric ulcer in one) and two with intra-abdominal bleeding requiring relaparotomy. All five bleeding complications occurred after gastrointestinal cancer surgery with anastomosis, and four out of five cases occurred during heparin bridging period (POD 3-5), except for the case of bleeding from gastric Dieulafoy ulcer, which occurred on POD 23 after persistent postoperative ileus. The mortality rates in the WF, DOAC-HB, and DOAC-NHB groups were 1.3%, 0.0%, and 1.4%, respectively (\( P = .791 \)).

### 3.3 | Risk factors affecting thromboembolic and bleeding complications

Univariate and multivariate analyses of postoperative bleeding complications in the cohort were conducted and are shown in Table 4. Univariate analysis revealed that only DOAC treatment with heparin bridging is associated with postoperative bleeding. Multivariate analysis also showed that DOAC treatment with heparin bridging is independently and significantly associated with postoperative bleeding (odds ratio = 11.60, \( P = .028 \)).

## DISCUSSION

In this study, which reviewed 334 patients who received ACT and underwent elective GE surgery, it was found that the incidences of overall postoperative complication, major bleeding complication, and thromboembolism were 28.4%, 5.1%, and 0.6%, respectively. Thirty-four patients (33.0%) treated with DOACs received perioperative heparin bridging. Surgical blood loss and rate of RBC transfusion were identical between the groups, and thromboembolism was observed only in the WF group (0.9% of patients in the WF group). The incidence of major postoperative bleeding was significantly higher in the DOAC-HB group than in the other groups, and multivariate analysis showed that DOAC therapy with heparin bridging is the most significant risk factor of major postoperative bleeding (odds ratio = 11.60, \( P = .028 \)). Therefore, perioperative bridging with heparin is not recommended during DOAC therapy interruption even for patients who undergo major GE surgery.

Currently, DOACs are increasingly prescribed for the prevention of arterial or venous thromboembolism. In 2011, dabigatran was approved and is indicated for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation. Factor Xa inhibitors were then launched with the same
indications. They are "easy-to-use" drugs with a wide range of safety. Compared to warfarin, DOACs have superior pharmacological properties such as better dose-response, less difference in anticoagulant activity between individuals, no effect of vitamin K intake on anticoagulant activity, and few drug interactions.5,23 Clinically, DOAC therapy also has many advantages including a 19% reduction in mortality and a 52% reduction in the incidence of intracranial hemorrhage compared to warfarin therapy.5,23 There is strong evidence from large-scale randomized controlled trials supporting the use of all four DOAC agents, and the results of a meta-analysis on these four agents have been published in The Lancet.5 The efficacy of DOACs (in preventing thromboembolism) is significantly higher than that of warfarin, and the safety of DOACs (in preventing bleeding events) is similar to that of warfarin.

DOACs are fast-acting agents that reach peak blood concentration 0.5–5 hours after administration. The half-lives of DOACs are also short (approximately 12 hours), and their anticoagulant effect fades within 48 hours after their withdrawal.9 It has been reported that the anti-factor Xa activity of factor Xa inhibitors fades within 48 hours of last intake in patients who receive them once a day (for example, rivaroxaban and edoxaban), and it fades within 36 hours in patients who receive them twice a day (for example, apixaban).24,25 Therefore, careful assessment of the risks and benefits to patients is necessary when DOAC therapy is stopped for longer than 36–48 hours.

The recently updated guideline on GE endoscopy and antithrombotic therapy9 recommends discontinuation of DOAC therapy on the morning of the procedure and resumption of DOAC therapy on the morning after the procedure in patients at high risk of bleeding. However, there is no evidence or guideline yet on GE surgery for patients who are administered DOACs; therefore, the safety of surgical procedures, including open GE surgery and laparoscopic GE surgery, should be assessed. This study showed that perioperative management using DOACs without heparin bridging is safe and feasible even for patients who undergo GE surgery.

| Variables                     | WF (n = 231) | DOAC-HB (n = 34) | DOAC-NHB (n = 69) | P value |
|-------------------------------|-------------|-----------------|------------------|--------|
| Postoperative complication, n (%) |             |                 |                  |        |
| C-D class 0                   | 166 (71.9)  | 18 (52.9)       | 55 (79.7)        | .071   |
| C-D class 1                   | 13 (5.6)    | 3 (8.8)         | 6 (8.7)          |        |
| C-D class 2                   | 32 (13.9)   | 6 (17.6)        | 4 (5.8)          |        |
| C-D class 3 or higher         | 20 (8.7)    | 7 (20.6)        | 4 (5.8)          |        |
| Postop. bleeding complication, n (%) |             |                 |                  | .011   |
| Luminal bleeding, n (%)       | 9 (3.9)     | 3 (8.8)         | 0 (0.0)          |        |
| Abdominal bleeding, n (%)     | 1 (0.4)     | 2 (5.9)         | 0 (0.0)          |        |
| Abdominal wall hematoma, n (%)| 0 (0.0)     | 0 (0.0)         | 1 (1.4)          |        |
| Intracranial hemorrhage, n (%)| 1 (0.4)     | 0 (0.0)         | 0 (0.0)          |        |
| Postop. thrombotic complication, n (%) |     |                 |                  | .637   |
| Cerebral infarction, n (%)    | 1 (0.4)     | 0 (0.0)         | 0 (0.0)          |        |
| Pulmonary embolism, n (%)     | 1 (0.4)     | 0 (0.0)         | 0 (0.0)          |        |
| Operative mortality, n (%)    | 3 (1.3)     | 0 (0.0)         | 1 (1.4)          | .791   |
| Length of postop. stay, d, median (range) | 14 [3-121] | 12.5 [3-64]    | 11 [3-147]      | .009   |

Note: Bold value indicates statistically significant.
Abbreviations: C-D, Clavien-Dindo; DOAC, direct oral anticoagulant; NA, not available; Postop., postoperative; WF, warfarin.

FIGURE 3 Incidence of postoperative bleeding and thromboembolic complications in each group. Thromboembolic complications only occurred in 2 of the 231 patients (0.9%) in the WF group, but thromboembolism did not occur in the patients treated with DOACs. The incidence of postoperative bleeding complication was significantly higher in the DOAC-HB group than in the WF group and the DOAC-NHB group (14.7% vs 4.8% vs 1.4%, P = .011). In the DOAC-NHB group, only 1 case of postoperative bleeding (abdominal wall hematoma) was observed. Abbreviations: DOAC, direct oral anticoagulant; HB, heparin bridging; NHB, non-heparin bridging; WF, warfarin
With regard to the perioperative management of patients who received DOAC therapy, heparin replacement after cessation of DOAC therapy was initially recommended in the guidelines for gastrointestinal endoscopy or non-cardiac surgery. However, the therapeutic effect of DOACs diminishes shortly after onset of action, and the major adverse effects of heparin replacement (including increased postoperative bleeding) were identified in the BRIDGE study or in other studies. The most recently updated guidelines recommend DOAC withdrawal for only a short period (36–48 hours) during the surgery and procedure but did not recommend heparin bridging during DOAC cessation even for procedures associated with a high risk of bleeding.

Several reviews and large-scale cohort studies also suggest that perioperative management of patients using DOACs without heparin bridging is safe and feasible during non-cardiac surgery. A recently published prospective multicenter cohort study (the PAUSE study) examined outcomes in 3007 adult patients with atrial fibrillation who received DOAC therapy and underwent an elective surgery or procedure. DOAC therapy was interrupted 1–2 days prior and resumed 1–2 days after the surgery or procedure. The rate of major bleeding 30 days after the surgery or procedure was 0.90%–1.85%, and the rate of arterial thromboembolism was 0.16%–0.60%. The study suggested that a standardized perioperative DOAC management strategy without heparin bridging can be safely used for patients with atrial fibrillation who undergo surgery. Although the patients in this study underwent a relatively small number of major digestive surgeries, the optimal DOAC therapy without heparin bridging is recommended even for patients who undergo surgeries with a high risk of bleeding such as GE surgery. Our study also showed that perioperative DOAC management without heparin bridging is safe and feasible even for patients who undergo GE surgery.

In this study, the rate of postoperative bleeding complication was significantly higher in the DOAC-HB group than in the other groups, and luminal (gastrointestinal) bleeding was the most frequent type of bleeding. Heparin bridging may accelerate the incidence of luminal bleeding especially in patients who undergo GE surgery with gastrointestinal anastomosis. The correlation between DOAC therapy with heparin bridging and postoperative luminal bleeding should be further investigated.

This study has some limitations. First, it is a retrospective review from a single center, and this reduces the strength of the conclusion. This limitation will be mitigated in a later follow-up study. Second, our institution is a high-volume tertiary referral hospital for surgical patients who receive antithrombotic therapy; therefore, our findings may not be generalizable to lower-volume centers. This limitation can be minimized by conducting prospective multi-institutional studies.

5 | CONCLUSIONS

This study, in reviewing 334 patients who received ACT and underwent elective GE surgery, showed that DOAC therapy with heparin bridging is the most significant risk factor for postoperative bleeding complication. Perioperative bridging with heparin is not recommended during DOAC therapy interruption even for patients who undergo major GE surgery.
REFERENCES

1. Connolly SJ, Ezekowitz MD, Yusuf S,ikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.
2. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.
3. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.
4. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.
5. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenedayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.
6. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al. Perioperative bleeding and thromboembolic events with dabigatran compared with warfarin. Circulation. 2012;126(3):343–8.
7. Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Outcomes of temporary interruption of rivaroxaban in patients with nonvalvular atrial fibrillation. Circulation. 2014;129(18):1850–9.
8. Dubois V, Dincq A-S, Douffils J, Iccx B, Samama C-M, Dogné J-M, et al. Perioperative management of patients on direct oral anticoagulants. Thromb J. 2017;15(1):14.
9. Kato M, Uedo N, Hokimoto S, Ieko M, Higuchi K, Murakami K, et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment: 2017 appendix on anticoagulants including direct oral anticoagulants. Dig Endosc. 2018;30(4):433–40.
10. Acosta RD, Abraham NS, Chandrasekhar V, Chathadi KV, Early DS, Eloubeidi MA, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc. 2016;83(1):3–16.
11. Fujikawa T, Tanaka A, Abe T, Yoshimoto Y, Tada S, Maekawa H, et al. Does antiplatelet therapy affect outcomes of patients receiving abdominal laparoscopic surgery? Lessons from more than 1,000 laparoscopic operations in a single tertiary referral hospital. J Am Coll Surg. 2013;217(6):1044–53.
12. Fujikawa T, Tanaka A, Abe T, Yoshimoto Y, Tada S, Maekawa H. Effect of antiplatelet therapy on patients undergoing gastrointestinal surgery: thromboembolic risks versus bleeding risks during its perioperative withdrawal. World J Surg. 2015;39(1):139–49.
13. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–70.
14. Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age ≥65, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J. 2008;156(1):57–64.
15. Zhu W-G, Xiong Q-M, Hong K. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation. Texas Hear Inst J. 2015;42(1):6–15.
16. Mitchell LB, Southern DA, Galbraith D, et al. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores. Heart. 2014;100(19):1524–30.
17. Ntaios G, Lip GHY, Makaritsis K, Papavasileiou V, Vemmou A, Koroboki E, et al. CHADS2, CHA2DS2-VASc, and long-term stroke outcome in patients without atrial fibrillation. Neurology. 2013;80(11):1009–17.
18. Lip GHY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57:173–80.
19. Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer. 1992;67(4):773–5.
20. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
21. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4.
22. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
23. Desai J, Granger CB, Weitz JI, Aisenberg J. Novel oral anticoagulants in gastroenterology practice. Gastrointest Endosc. 2013;78(2):227–39.
24. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75(2):476–87.
25. Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd R, et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol. 2014;6:179–87.
26. Fujimoto K, Fujiyoshi M, Kato M, Higuchi K, Iwakiri K, Sagamori Y, et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc. 2018;30(4):433–40.
27. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ J. 2014;78(8):1997–2021.
28. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373(9):823–33.
29. Raval AN, Cigarroa JE, Chung MK, Diaz-Sandoval LJ, Diercks D, Piccini JP, et al. Management of patients on non-Vitamin K antagonist oral anticoagulants in the acute care and perioperative setting: A Scientific Statement From the American Heart Association. Circulation. 2017;135(10):e647.

DISCLOSURES
Conflicts of Interest: All authors declare no conflicts of interest.

Ethical Approval: This work was approved by the ethics committee of Kokura Memorial Hospital (#19061903).

Author Contributions: TF: study conception and design. TF, RT and SN: acquisition of data. TF: analysis and interpretation of data; drafting of manuscript. TF and SN: critical revision.

ACKNOWLEDGEMENTS
We would like to thank Editage (www.editage.com) for English language editing.

ORCID
Takahisa Fujikawa https://orcid.org/0000-0002-4543-9282
30. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–93.

31. Verma A, Ha ACT, Rutka JT, Verma S. What surgeons should know about non-vitamin K oral anticoagulants. JAMA Surg. 2018;153(6):577.

32. Douketis JD, Spyropoulos AC, Duncan J, Carrier M, Le Gal G, Tafur AJ, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2019;179(11):1469.

How to cite this article: Fujikawa T, Takahashi R, Naito S. Perioperative antithrombotic management of patients who receive direct oral anticoagulants during gastroenterological surgery. Ann Gastroenterol Surg. 2020;4:301–309. https://doi.org/10.1002/ags3.12328